Glycoprotein IIIA Gene ( PIA ) Polymorphism and Aspirin Resistance: Is There Any Correlation?
- 1 June 2005
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (6) , 1013-1018
Abstract
BACKGROUND: Platelet glycoprotein (GP) IIb/IIIa receptors play an inevitable role in platelet aggregation. The GP IIIa gene is polymorphic ( PIA1/PIA2) and the presence of a PIA2 allele might be associated with an increased risk for acute coronary syndrome (ACS). OBJECTIVE: To examine the prevalence of the PIA2 allele in patients with ACS and in subjects with or without aspirin resistance. METHODS: The prevalence of the PIA2 allele was assessed in 158 patients with ACS and PIA2 compared with its prevalence in 199 healthy volunteers. The antiplatelet efficacy of aspirin was examined in all patients with ACS, as well as in 69 individuals who had suffered ischemic stroke and in 58 high-risk subjects without any known ischemic vascular events. RESULTS: PIA2 prevalence was significantly higher in patients with ACS (59/158) than in the control group (51/199; p < 0.05). Carriers of the PIA2 allele had a significantly higher risk of developing ACS, even after an adjustment to the risk factors (OR 5.74; 95% CI 1.75 to 18.8; p = 0.004). The occurrence of the PIA2 allele was significantly higher among patients with aspirin resistance than in subjects who demonstrated an appropriate response to the drug (allele frequencies, 0.21 vs 0.14; p < 0.05). All patients homozygous for the PIA2 allele had an inadequate platelet response to aspirin. CONCLUSIONS: Our results support the hypothesis that carriers of the PIA2 allele might have an increased risk for ACS. PIA2 homozygosity was associated with an inadequate response to aspirin therapy. Our data further suggest that patients with PIA2 allele homozygosity might benefit from antiplatelet therapy based on adenosine diphosphate antagonists throughout secondary treatment for prevention of ACS.Keywords
This publication has 22 references indexed in Scilit:
- PLATELET GLYCOPROTEIN GENE POLYMORPHISMSAND RISKOF THROMBOSIS: FACTSAND FANCIESReviews in Clinical and Experimental Hematology, 2001
- Platelet PlA2 Polymorphism and Thromboembolic Events: From Inherited Risk to PharmacogeneticsJournal of Thrombosis and Thrombolysis, 1999
- Pla1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplastyThe American Journal of Cardiology, 1998
- Coronary Thrombosis and the Platelet Glycoprotein IIIA Gene PLA2 PolymorphismThrombosis and Haemostasis, 1998
- Association of the Platelet Glycoprotein IIIa PIA1/A2 Gene Polymorphism to Coronary Artery Disease but not to Nonfatal Myocardial Infarction in Low Risk PatientsThrombosis and Haemostasis, 1998
- The Leu33/Pro Polymorphism (PIA1/PIA2 ) of the Glycoprotein IIIa (GPIIIa) Receptor Is Not Related to Myocardial Infarction in the ECTIM StudyThrombosis and Haemostasis, 1997
- Glycoprotein IIIa polymorphism and risk of myocardial infarctionCardiovascular Research, 1997
- A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary ThrombosisNew England Journal of Medicine, 1996
- Development of aspirin resistance in persons with previous ischemic stroke.Stroke, 1994
- Aspirin response and failure in cerebral infarction.Stroke, 1993